Phase I Clinical Trial - Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- Osteoarthritis,Knee
- Sponsor
- EMO Biomedicine Corporation
- Enrollment
- 12
- Locations
- 1
- Primary Endpoint
- Safety of RegStem by incidence of adverse events and changes in physical examinations, vital signs and the results of clinical lab tests.
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
Osteoarthritis (OA) is a common and incurable disease for the elderly in Taiwan, so it is an important mission to develop a new treatment for OA. Recently, cellular therapy is a new and popular medical treatment around the world, one of them is "Mesenchymal Stromal Cells (MSCs)". MSCs are found in many tissues of human body and play an important role for repairing, regeneration, anti-inflammatory and chondrogenesis. So, MSC product, RegStem, for osteoarthritis treatment becomes a developing target for new generation drugs.
This study is to isolate and expand MSCs(RegStem) from infrapatellar fat pad of subject. When the number of MSCs expands to 1×10^8, cell will be cryopreserved in the liquid nitrogen tank until all release tests passed. On the distribution day, cell will be thawed and injected into joint cavity of patient (5×10^7). Subjects will be monitored after MSC product infusion of seven days, one month, six months and one year. The monitoring items include the changes of knee (by appearance, X-ray and MRI of knee) and pain improvement (by questionnaire).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Subjects who understand and sign the informed consent form for this study
- •Grade 2\~3 osteoarthritis according to the Kellgren-Lawrence grading scale with one-month X-ray
- •Age is 50\~75 years old
- •Postmenopausal women
- •VAS scores in 50 to 90 mm
Exclusion Criteria
- •Abnormal of liver and kidney: GOT and GPT \> 100 IU/L, BUN \>22 mg/dl and creatinine \> 1.2 mg/dl.
- •Positive serology for HIV, HTLV-1/2 and syphilis
- •Women who are pregnant or breast feeding
- •Serious pre-existing medical conditions: coagulation disorders, cardiovascular diseases (arrhythmias, myocardial infarction and surgery), renal diseases (chronic renal failure), liver diseases (cirrhosis), diabetes mellitus type I, cancer history.
- •Other joint diseases: knee deformity (knee varus greater than 10 degree or valgus greater than 20 degree), rheumatic arthritis, gouty arthritis, septic arthritis, serious meniscal tear, other autoimmune arthritis.
- •Skin inflammatory of knee
- •Knee pain caused by referred pain from spine disease or hip joint disease. Knee pain combined with pain from spine disease or hip disease.
- •Immunosuppressive state
- •Subjects who were injected with hyaluronic acid and PRP in the past 6 months
- •Body mass index (BMI) greater than 30
Outcomes
Primary Outcomes
Safety of RegStem by incidence of adverse events and changes in physical examinations, vital signs and the results of clinical lab tests.
Time Frame: 48 weeks
Clinical assessment of International Knee Documentation Committee (IKDC) score
Time Frame: 48 weeks
Assess symptoms of knee, sport activity and function of knee
Secondary Outcomes
- Clinical assessment of knee X-ray(48 weeks)
- Clinical assessment of visual analogue scale (VAS)(48 weeks)
- Clinical assessment of knee MRI(48 weeks)
- Clinical assessment of Knee injury and Osteoarthritis Outcome Score (KOOS)(48 weeks)